Spero Therapeutics LLC, launched in 2013 with seed funding from Atlas Venture with a focus on developing novel antibiotics for gram-negative infections, has signed its first partner. The Cambridge, MA-based biotech announced April 9 that it will partner with Roche on preclinical development of a molecule addressing an undisclosed novel target that has shown the ability in preclinical studies to shut off the effects of gram-negative pathogens. [See Deal]
Roche is providing non-dilutive R&D funding to Spero, which is about halfway through the IND-enabling work for the candidate, said...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?